ABSTRACT
I. INTRODUCTION Considerable advances in the understanding of the biology of chronic lymphocytic leuke mia (CLL) and cellular events responsible for the pathogenesis of the disease have oc curred over the past two decades (1). These have already contributed to better definition of the disease and its variants, more accurate diagnosis, and the introduction of more effective chemotherapy regimens (2,3).
